Orthocell has today published its Quarterly Report for the period ended 30 June 2024.
Highlights for this Quarter:
- Orthocell reports record quarterly revenue of $1.84 million and year-on-year growth of 30% to $6.72 million
- Strong balance sheet with $20.60 million cash at bank at the end of the quarter
- OCC to launch third revenue generating product in SmrtGraft™ for tendon repair
- Compelling 85% success rates from Remplir™ nerve repair study published in peer-reviewed clinical journal
- Outstanding 98.6% success rate from Striate+™ dental implant post-market clinical study
- Top-line results from Remplir™ US market authorisation study expected in Q4 CY24
Orthocell Managing Director, Paul Anderson, said:
“Orthocell has completed a record quarter with increasing revenues and strengthening the balance sheet. I am delighted with the performance of our distribution partners and the continued increase in product adoption. With a highly respected and experienced Board in place, we are in a strong position to continue to gain commercial traction and drive our innovative products into global markets.”
Click here to read today’s ASX release.